Virax Biolabs Group Ltd - Class A
Research Virax Biolabs Group Ltd - Class A (VRAX) on Bullrun: market cap USD 19.04M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerVRAX
- ExchangeNASDAQ
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 19.04M
- Financial periodQ1 2026
Valuation Snapshot
latest market cap is USD 19.04M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 6.33K | -USD 6.06M | -USD 5.17M | -838.2% | -1.62 | USD 4.23M | USD 377.00K | USD 5.70M |
| FY2024 | USD 156.42K | -USD 6.73M | -USD 7.41M | 32.3% | -3.36 | USD 3.59M | USD 224.30K | USD 5.37M |
| FY2023 | USD 8.56K | -USD 5.46M | -USD 4.36M | -15.9% | -5.13 | USD 9.35M | USD 146.25K | USD 9.13M |
| FY2022 | USD 0 | -USD 1.71M | -USD 809.07K | n/a | -1.5 | USD 21.76K | USD 390.00K | -USD 974.58K |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 19.04M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 2.29M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 9.77M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 2.64M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 9.36M | n/a | n/a | n/a |
About Virax Biolabs Group Ltd - Class A
Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China. The company offers ViraxImmune, a T cell-based immune profiling and diagnostic platform for post-acute infection syndromes, including long COVID, myalgic encephalomyelitis / chronic fatigue syndrome, and post-treatment Lyme disease.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Virax Biolabs Group Ltd - Class A's market cap?
Virax Biolabs Group Ltd - Class A's market capitalization is USD 19.04M.
What does Virax Biolabs Group Ltd - Class A do?
Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China. The company offers ViraxImmune, a T cell-based immune profiling and diagnostic platform for post-acute infection syndromes, including long COVID, myalgic encephalomyelitis / chronic fatigue syndrome, and post-treatment Lyme disease.